ling, general and administrative expenses and $11.7 million in
Income tax expense related to SFAS 123(R).
CEPHALON, INC. AND SUBSIDIARIES
"ADJUSTED" CONSOLIDATED SALES DETAIL *
(In thousands)
(Unaudited)
Three Months Ended
December 31,
2007
United
States Europe Total
Sales:
PROVIGIL $208,245 $11,237 $219,482
GABITRIL 10,828 400 11,228
CNS 219,073 11,637 230,710
ACTIQ 42,310 12,027 54,337
Generic OTFC 31,471 - 31,471
FENTORA 33,912 - 33,912
AMRIX 8,401 - 8,401
Pain 116,094 12,027 128,121
Other 15,396 65,270 80,666
$350,563 $88,934 $439,497
Three Months Ended
December 31,
2006
United
States Europe Total
Sales:
PROVIGIL $190,838 $13,833 $204,671
GABITRIL 12,805 806 13,611
CNS 203,643 14,639 218,282
ACTIQ 100,882 8,039 108,921
Generic OTFC
'/>"/>
SOURCE Cephalon, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Related biology technology :1.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results2.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain3.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results4.
CNS Response Announces Fiscal Third Quarter 2007 Results5.
Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results6.
China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results7.
XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 20078.
Carrington Reports Second Quarter 2007 Results9.
Avitar Reports Third Quarter Financial Results for Fiscal 200710.
Response Genetics Reports Second Quarter 2007 Financial Results11.
Martek to Announce Third Quarter 2007 Results on September 5, 2007